Literature DB >> 10386614

Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2.

M Pirard1, G Matthijs, L Heykants, E Schollen, S Grünewald, J Jaeken, E van Schaftingen.   

Abstract

Seven mutant forms of human phosphomannomutase 2 were produced in Escherichia coli and purified. These mutants had a Vmax of 0.2-50% of the wild enzyme and were unstable. The least active protein (R141H) bears a very frequent mutation, which has never been found in the homozygous state whereas the second least active protein (D188G) corresponds to a mutation associated with a particularly severe phenotype. We conclude that total lack of phosphomannomutase 2 is incompatible with life. Another conclusion is that the elevated residual phosphomannomutase activity found in fibroblasts of some patients is contributed by their mutated phosphomannomutase 2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386614     DOI: 10.1016/s0014-5793(99)00673-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

1.  Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients.

Authors:  S Vuillaumier-Barrot; G Hetet; A Barnier; T Dupré; M Cuer; P de Lonlay; V Cormier-Daire; G Durand; B Grandchamp; N Seta
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

2.  Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia.

Authors:  P Briones; M A Vilaseca; E Schollen; I Ferrer; M Maties; C Busquets; R Artuch; L Gort; M Marco; E van Schaftingen; G Matthijs; J Jaeken; A Chabás
Journal:  J Inherit Metab Dis       Date:  2002-12       Impact factor: 4.982

3.  Congenital disorder of glycosylation type Ia presenting with hydrops fetalis.

Authors:  J M van de Kamp; D J Lefeber; G J G Ruijter; S J Steggerda; N S den Hollander; S M Willems; G Matthijs; B J H M Poorthuis; R A Wevers
Journal:  J Med Genet       Date:  2006-12-08       Impact factor: 6.318

4.  High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency).

Authors:  S Grünewald; E Schollen; E Van Schaftingen; J Jaeken; G Matthijs
Journal:  Am J Hum Genet       Date:  2001-01-11       Impact factor: 11.025

5.  The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations.

Authors:  B Pérez; P Briones; D Quelhas; R Artuch; A I Vega; E Quintana; L Gort; M J Ecay; G Matthijs; M Ugarte; C Pérez-Cerdá
Journal:  JIMD Rep       Date:  2011-06-22

6.  Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.

Authors:  Vandana Sharma; Mie Ichikawa; Ping He; David A Scott; Yalda Bravo; Russell Dahl; Bobby G Ng; Nicholas D P Cosford; Hudson H Freeze
Journal:  J Biol Chem       Date:  2011-09-26       Impact factor: 5.157

7.  Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie.

Authors:  T Imbach; B Schenk; E Schollen; P Burda; A Stutz; S Grunewald; N M Bailie; M D King; J Jaeken; G Matthijs; E G Berger; M Aebi; T Hennet
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

8.  Clinical utility gene card for: Phosphomannomutase 2 deficiency.

Authors:  Jaak Jaeken; Dirk Lefeber; Gert Matthijs
Journal:  Eur J Hum Genet       Date:  2014-01-15       Impact factor: 4.246

9.  Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate-mannose synthase gene deletion mutants.

Authors:  A Garami; A Mehlert; T Ilg
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 10.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.